Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this trial is to demonstrate that the fixed-dose combination of
T80/HCTZ25 is superior as first line therapy in reducing seated trough cuff Systolic Blood
Pressure(SBP) compared to the monotherapy of T80 in patients with grade 2 or grade 3
hypertension (SBP>=160 mmHg and Diastolic Blood Pressure(DBP)>=100 mmHg).